filmov
tv
MindMed investigating potential benefits of DMT in upcoming Phase 1 clinical trial collaboration
Показать описание
Mind Medicine Inc (NEO:MMED) (OTCQB:MMEDF) CEO JR Rahn tells Proactive it is pursuing research into DMT, the active ingredient in Ayahuasca.
Rahn says its part of a research and development collaboration that the psychedelics company has with the University Hospital Basel’s Liechti Lab. MindMed will provide startup funding for a Phase 1 clinical trial looking at intravenous dosing regimen options for DMT.
Rahn says its part of a research and development collaboration that the psychedelics company has with the University Hospital Basel’s Liechti Lab. MindMed will provide startup funding for a Phase 1 clinical trial looking at intravenous dosing regimen options for DMT.
0:06:06
0:04:06
0:00:16
0:31:22
0:05:09
0:07:49
0:17:43
0:06:59
0:11:57
0:06:52
0:09:56
0:21:09
0:11:22
0:23:15
0:08:07
0:09:04
0:10:44
0:44:43
0:22:02
0:05:54
0:27:07
0:08:37
0:27:02
0:12:33